Press Releases

Press Releases

December 1, 2023
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 9, 2023
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
November 6, 2023
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
November 3, 2023
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 2, 2023
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
October 21, 2023
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
October 17, 2023
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
October 6, 2023
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 20, 2023
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
September 1, 2023
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 27